Skip to content

The efficacy of fingolimod in enhancing recovery after traumatic spinal cord injury

The efficacy of fingolimod in enhancing neurological recovery after traumatic spinal cord injury

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240701062291N1
Enrollment
36
Registered
2024-08-20
Start date
2024-08-22
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spinal cord injury. Injury, poisoning and certain other consequences of external causes

Interventions

Intervention 1: Intervention group: In the intervention group, patients with spinal cord injury received fingolimod (Aburihan Pharmaceutical Company)in addition to methylprednisolone (MPSS-Exir Aburih

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: stable hemodynamic status age between 20 and 60 Patients with acute traumatic spinal cord injury who referred within the first 8 hours

Exclusion criteria

Exclusion criteria: acute non traumatic spinal cord injury Acute spinal cord injury that has been more than 8 hours since the trauma Spinal cord injuries caused by firearms or cold weapons

Design outcomes

Primary

MeasureTime frame
Sensorimotor status of patients. Timepoint: Sensory and motor condition of patients are evaluated based on clinical examination immediately after administration (Before the intervention begins) and then at intervals of one month, three months, six months and one year after the intervention. Method of measurement: the sensory-motor condition of patients are evaluated based on American Spinal Injury Association Impairment Scale (AISA).;Sphincter function. Timepoint: administration and evaluation at intervals of six months and one year. Method of measurement: clinical examination and questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Nazarpour

Mashhad University of Medical Sciences

nazarpoursh991@mums.ac.ir+98 51 3766 1434

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026